Cephalon Inc. March 14 filed a complaint in the U.S. District Court for the District of Delaware alleging that Dr. Reddy’s Laboratories Ltd. infringed a patent on its cancer drug Treanda (Cephalon, Inc. v. Dr. Reddy’s Labs., Ltd.).
On Feb. 10, Dr. Reddy’s notified Cephalon, which was acquired by Teva Pharmaceuticals Inc. in 2011, that it had filed an abbreviated new drug application (ANDA), with paragraph IV certification, with the Food and Drug Administration seeking approval of its generic version of Treanda prior to the patent’s expiration.
According to the complaint, Treanda (bendamustine hydrochloride) is indicated to treat ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.